Aptevo reports 93% clinical benefit rate in frontline AML
Aptevo reported a 93% clinical benefit rate for mipletamig with venetoclax and azacitidine in evaluable frontline TP53-mutated AML patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Aptevo reports 93% clinical benefit rate with mipletamig triplet
Aptevo Therapeutics said mipletamig triplet produced a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML, with remission results described as nearly doubling published ven/aza outcomes.
Aptevo reports 93% clinical benefit rate in TP53-mutated AML
Aptevo says mipletamig triplet delivered a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML.